A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer ; volume:14 ; number:1 ; day:8 ; month:5 ; year:2023 ; pages:1-18 ; date:12.2023
Discover oncology ; 14, Heft 1 (8.5.2023), 1-18, 12.2023
- Urheber
-
Man, Yuxin
Dai, Chao
Guo, Qian
Jiang, Lingxi
Shi, Yi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12672-023-00669-4
- URN
-
urn:nbn:de:101:1-2023090708222102036385
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Man, Yuxin
- Dai, Chao
- Guo, Qian
- Jiang, Lingxi
- Shi, Yi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors